#India #Mumbai #CDMO #Piramal Pharma #Net Promoter Score

Piramal Pharma Solutions: A Testament to Excellence

Piramal Pharma Solutions, a global leader in contract development and manufacturing (CDMO) services, recently announced an impressive Net Promoter Score (NPS) of 55 for the fiscal year 2025, which spans from April 2024 to March 2025. This remarkable score not only highlights the company’s unwavering commitment to excellence but also showcases its focus on stakeholders’ needs.

Understanding Net Promoter Score

The NPS is a widely recognized industry benchmark that gauges customer loyalty by measuring the likelihood of customers recommending a company's products or services to others. Piramal Pharma Solutions conducts annual customer surveys facilitated by its Customer Centricity Team, with results validated by DNV, an independent assurance and risk management firm. This rigorous process ensures the accuracy and accountability of their customer feedback and performance assessment.

The analysis of the survey results drives the formulation of subsequent business strategies and action plans tailored for the upcoming year. These strategies are implemented across the organization to optimize service delivery and strengthen customer engagement across various domains.

Surpassing Industry Norms

This year's NPS of 55 from Piramal Pharma Solutions significantly surpasses the negative averages reported by many competing CDMOs, solidifying the company's reputation as an industry leader. The impressive score reflects the organization's unwavering dedication to a stakeholder-centric approach, deeply embedded within its global network. The company consistently prioritizes its stakeholders in all its initiatives and decisions, aligning operational objectives and business strategies with their needs.

By enhancing communication and collaboration at every level, Piramal Pharma Solutions fosters long-term partnerships and deepens customer relationships. Rather than merely aiming for customer satisfaction, the organization aspires to enchant its customers by exceeding their expectations.

Innovation in Strategic Initiatives

Peter DeYoung, CEO of Piramal Global Pharma, stated, "The insights gained from this year's NPS survey will guide our strategic initiatives and enhance customer engagement and operational efficiency moving forward. We remain committed to continuous improvement by refining our service offerings and upgrading our processes to ensure we deliver maximum value to our clients, consumers, and patients worldwide."

The Customer Centricity Team plays a critical role in maintaining the integrity of the NPS data by collaborating with various departments throughout the external assurance process. This team manages data collection and presents findings to the board, which reviews the information for inclusion in the annual sustainability report, certified by DNV. Such structured approaches underscore Piramal Pharma Solutions' commitment to transparency and accountability in all performance indicators.

About Piramal Pharma Solutions

Piramal Pharma Solutions is a contract development and manufacturing organization (CDMO) that offers comprehensive end-to-end development and manufacturing solutions throughout the entire drug lifecycle. The organization meets customer needs through an integrated global network of facilities across North America, Europe, and Asia. This extensive network enables the delivery of a full range of services, including drug discovery solutions, process development, clinical trial supplies, and the commercial supply of active pharmaceutical ingredients and finished dosage forms.

Piramal Pharma Solutions also specializes in highly potent active pharmaceutical ingredient development and manufacturing, antibody-drug conjugates, sterile fill-finish, peptide products, and related services, as well as biological product development and manufacturing, such as vaccines and gene therapy products.

To learn more about Piramal Pharma Solutions and its dedication to excellence, visit their official website and follow them on social media.